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Abstract 
Purpose: To investigate the pathogenesis of high fat diet (HFD)-induced hyperlipidemia (HLP) in mice, 
rats and hamsters and to comparatively evaluate their sensitivity to HFD. 
Methods: Mice, rats and hamsters were fed with high-fat diet formulation (HFD, n = 8) or a control diet 
(control, n = 8) for 4 weeks. Changes in body weight, relative liver weight, serum lipid profile, 
expressions of hepatic marker gene of lipid metabolism and liver morphology were observed in three 
hyperlipidemic models.  
Results: Elevated total cholesterol (TC), triglyceride, low density lipoprotein-cholesterol (LDL-C) and 
high density lipoprotein-cholesterol (HDL-C) levels and body weight were observed in all hyperlipidemic 
animals (p < 0.05), while hepatic steatosis was manifested in rat and hamster HLP models, and 
increased hepatic TC level was only seen (p < 0.05) in hamster HLP model. Suppression of HMG-CoA 
reductase and up-regulation of lipoproteinlipase were observed in all HFD groups. Hepatic gene 
expression of LDLR, CYP7A1, LCAT, SR-B1, and ApoA I, which are a response to reverse cholesterol 
transport (RCT), were inhibited by HFD in the three models. Among these models, simultaneous 
suppression of HMG-CR, LCAT, LDLR and SR-BI and elevated LPL were features of the hamster 
model. 
Conclusion: As the results show, impaired RCT and excessive fat accumulation are major contributors 
to pathogenesis of HFD-induced murine HLP. Thus, the hamster model is more appropriate for 
hyperlipidemia research.  
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Hyperlipidemia (HLP) is a disorder of lipid 
metabolism characterized by abnormally 
elevated levels of one or more lipids and/or 
lipoproteins in the blood [1], which has been 
identified as a clinical risk factor for 
atherosclerosis and cardiovascular disease [2]. 
Moreover, it is one of the major predisposing 
factors for cancer [3] and diabetes [4]. In the 
United States, approximately one of six adults 
suffers from hyperlipidemia [5]. Therefore, it is 
necessary to investigate pathogenesis of HLP 
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and to find effective hypolipidemic agents. Since 
animal model of HLP plays a critical role in 
mimicking the disease pathogenesis for human 
HLP as well as evaluating hypolipidemia agents, 
multiply animal models have been extensively 
explored.  
 
Although the pathogenesis of hyperlipidemia is 
multifactorial, which resulted to complex 
interactions between genetic, dietary and 
environmental factors, excessive absorption of 
lipids from a high-fat diet (HFD) or abnormal lipid 
metabolism in the body is one of the major 
contributing factors of hyperlipidemia [6]. 
Therefore, in the last ten years HFD-induced 
hyperlipidemic animal models have been 
commonly used worldwide. It is well documented 
that rats [7], mice [8], rabbits [9], guinea pig [10], 
hamster [11], and gerbil [12] are used for 
modeling human HLP. Among them, rats, 
hamster and mice are the most extensively used 
animals [13-19]. However, the molecular basis of 
pathogenesis in hyperlipidemic rats, hamster and 
mice model induced by HFD remain unclear, 
which limits its predictability and accuracy on 
evaluating lipid-lowering agents for human HLP.  
 
In recent years, a larger number of innovative 
lipid-lowering agents have emerged, including 
PSCK9 inhibitor and LXRβ agonist, but it 
remains questionable whether these routine 
animal models will be suitable for evaluating 
new-target agents. Undoubtedly, elucidating the 
molecular mechanism of generally used animal 
model will facilitate evaluation of new lipid-
lowering agent. Based on preliminary 
optimization of the HLP model in our laboratory 
and wide investigation of literature, modified HFD 
formulation containing bile acid and 
propylthiouracil is chosen for this research, in 
which rational time frame and efficiency of 
modeling is taken into consideration. Therefore, 
our studies focused on re-evaluating HFD-
induced hyperlipidemic animal models by 
assessing hepatic marker genes of lipid 
metabolism in combination with investigating 







All animal experimental protocols were approved 
by the Animal Ethics Committee of Guangdong 
Provincial Engineering Technology Institute of 
Traditional Chinese Medicine (Guangzhou, 
Guangdong, China) (no. LN:SYXK2010-0059). 
The care and treatment of the animals were 
conducted in accordance with the guidelines 
(Publication no. 85-23, revised 1996) provided by 
the National Institute of Health (Bethesda, MA, 
USA) and U.S. Department of Agriculture 




Total cholesterol(TC), triglyceride (TG), high-
density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C) kits were 
purchased from Nanjing Jiancheng 
Bioengineering Institute (Nanjing, Jiangsu, 
China). Ethanol and isopropanol of analytical 
grade were purchased from Dikma Technologies, 
Inc. (Beijing, China). TRIzol® reagent was 
purchased from Invitrogen Life Technologies 
(Carlsbad, CA, USA). The RevertAid™ First 
Strand cDNA Synthesis kit and the Maxima™ 
SYBR-Green/Fluorescein qPCR Master mix (2 ×) 
were purchased from Thermo Fisher Scientific 
(Burlington, ON, Canada). 
 
Animals, diets and treatments 
 
Twenty male Sprague-Dawley (SD) rats weighing 
between 180 and 220 g, and twenty male NIH 
mice weighing between 18 and 22 g were 
purchased from the Guangdong Medical 
Laboratory Animal Center (Guangzhou, 
Guangdong, China) (nos. 44007200015094 and 
44007200015095), and twenty male golden 
hamster weighing between 120 and 150g were 
purchased from Vital River Laboratory Animal 
Technology Co. Ltd. (no. 11400700071275).  
 
All animals were kept in a specific pathogen free 
room under controlled conditions. A 12 h light-
dark cycle was maintained, with lights on 
between 7:00 am and 7:00 pm, and the 
temperature was maintained at 24 ± 1 oC. The 
animals were provided with standard laboratory 
diet and tap water and allowed to adapt to the 
environment for 1week prior to the start of the 
experiment. Afterward, the rats, mice and 
hamster were randomly divided into two groups 
with ten animals in each group. The animals in 
the normal control (NC) group were fed on a 
normal diet, while animals in the model group 
were fed with a high-fat diet (standard diet + 15 
% lard + 5 % cholesterol + 0.4 % bile salt + 0.5 
% propylthiouracil) by intragastic administration 
once per day, 20 mL/kg mice body weight, and 
10 mL/kg rat and hamster body weight for 4 
weeks. Then the animals were anesthetized in a 
10 % chloral hydrate and the blood and livers 
were collected. 
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At the end of the experiment, all feed were 
removed 12 h before euthanization. Blood was 
collected into the centrifuge tube from the 
abdominal aorta and left to coagulate at room 
temperature. The serum samples were obtained 
by centrifugation at 3,300 g, 4 oC for 10 min and 
stored at 4 oC for further analysis. 
 
The whole liver from each animal was 
immediately removed, washed with PBS, dried 
on filter paper, weighed and a slice of each 
sample was stored at 80 oC for further analysis. 
 
Measurement of Lipid Levels in the serum 
and liver 
 
The PCR primers used are listed in Table 1. The 
serum and liver levels of TC, TG, HDL-C and 
LDL-C were determined using the respective 
assay kits in accordance with the manufacturer's 
instructions. All samples were detected using the 
722 Grating Spectrometer (Shanghai Cany 
Precision Instrument, Co., Ltd., Shanghai, 
China). 
 
Quantitative PCR (qPCR) analysis of hepatic 
mRNA levels  
 
Total RNA was extracted from the liver samples 
using TRIzol reagent in accordance with the 
manufacturer's instructions. A total of 3 μg of 
total RNA was reverse - transcribed into cDNA 
using the First Strand cDNA Synthesis kit at 42 
oC for 1 h. qPCR was performed using the iQ5™ 
real-time PCR detection system (Bio-Rad, 
Hercules, CA, USA) and performed in a reaction 
mix containing 1 μL cDNA, 
 
Table 1: Primers for real-time RT-PCR 
 
Gene Forward Primer Reverse Primer Product 
(bp) 




ApoAI 5'-GTATGGCAGCAAGATG-3' 5'-AGGAGATTCAGGTTCAG-3' 149 
CYP7A1 5'-TTCTCAACGATACACTCT-3' 5'-CTCCATTCACTTCTTCAG-3' 168 
HMG-CR 5'-GGACCAACCTTCTACCTCAG-3' 5'-CTCACCAGCCATCACAGT-3' 128 
LCAT 5'-CCGCACCCTATGACTG-3' 5'-CAAGGCTATGCCCAAT-3' 126 
LDLR 5'-TGATGGAGACCGAGATTG-3' 5'-GCTGCGATGGATACACT-3' 259 
SR-B1 5'-TTCTACTTGTCTGTCTACT-3' 5'-GGTGTCGTTGTCATTG-3' 144 
LPL 5’-TGGCTCCAGAGTTTGA-3’ 5’-TTGAAGTGGCAGTTAGAC-3’ 170 
18S 5'-ACGGCTACCACATCC-3' 5'-CAGACTTGCCCTCCA-3' 162 





ApoAI 5'-AAGGCATCTAAAGGTTGT-3' 5'-TCAGGGTAGGGTGGTT-3' 149 
CYP7A1 5'-TGCCGTGTTGGTGAG-3' 5'-TTCGCAGAAGTAGTGTAAT-3' 291 
HMG-CR 5'-TGACGCTCTGGTGGA-3' 5'-GTTACTGGGTTTGGTTTAT-3' 249 




SR-B1 5'-TACTTGTCCGTCTACT-3' 5'-CGTGTCATT GTCATTG-3' 141 
LPL 5’-TGGCTCCAGAGTTTGA-3’ 5’-TTGAAGTGGCAGTTAGAC-3’ 170 
18S 5'-ACGGCTACCACATCC-3' 5'- CAGACTTGCCCTCCA-3' 162 
Hamster    
ABCA1 5'-GGTGTTCTTCCTCATTA-3' 5'-GGTGTTCTTCCTCATTA-3' 193 







HMG-CR 5'-GGGCAATAGGTCTT-3' 5'-ACTGGAAACGGATG-3' 234 
LCAT 5'-TTAGACGACAACAAG-3' 5'-TAGGCAGCATACAT-3' 179 
LDLR 5'-TGGTCATCCTCCTTGT-3' 5'-TCTTCCGTGGTCTTCT-3' 109 
SR-B1 5'-TGAGAAGCCAATAGTG-3' 5'-AAGACCAGAATGTTAGG-3' 183 
LPL 5'-TGACGGAGGAAGAGATT-3' 5'-TGCTGTGGTTGAAGTG-3' 134 
18S 5'-TCTATGAGGGCTACGC-3' 5'-CAGGGAGGAAGAGGAT-3' 215 
Gene symbols: HMG-CR, HMG-CoA reductase; CYP7A1, cholesterol 7α-hydroxylase; ABCA1, ATP-binding 
cassette transporterA1; LCAT, lecithin cholesterol acyltransferase; ApoA I, apolipoproteinAI; SR-B1, scavenger 
receptorB1; LDLR, low-density lipoprotein receptor; LPL, lipoproteinlipase 
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12.5 μL Maxima™ SYBR-Green/Fluorescein 
qPCR Master mix (2 ×), 1 μM forward primer and 
1 μM reverse primer in a total volume of 25 μL. 
The cDNA was amplified using specific primers 
under the following conditions for 45 cycles: 94 
oC for 30 s, an annealing temperature of 55 oC 
for 30 s and then 72 oC for 50 sec, with a final 
incubation at 72 oC for 7 min. The products were 
analyzed using the CT value and all values were 
normalized against the 18S mRNA level. The 





Liver samples were resected and fixed with 10 % 
formaldehydephosphate buffer saline (PBS, pH = 
7.4), and embedded in paraffin, sectioned, 
stained with hematoxylin/eosin (HE) and 




All continuous variables were expressed as 
mean ± SD（n = 8）, and analyses were 
performed with SPSS software, version 15.0 
(SPSS Science, Chicago, IL, USA). Statistical 
significance among groups was evaluated with 
One Way ANOVA (Dunnett's significant post-hoc 
test for pairwise multiple comparisons). Where 
linear regression was used, p < 0.05 was 




Growth parameters of hyperlipidemia animals 
fed on a high fat diet 
 
As demonstrated in Table 2, no significant 
difference between NC and model subgroups 
were found in the initial body weight, final body 
weight, body weight gain and relative liver weight 
coefficient respectively in groups of mice, rats or 
hamsters. 
 
Influence on serum and liver lipid levels of 
three murine models  
 
As the results in Table 3 show, serum levels of 
TC, TG were raised, whereas HDL-C, LDL-C, 
and liver lipid levels of TC, TG were slightly 
changed in mice HFD group. In rats model, 
serum TC, TG, HDL-C and LDL-C are increased 
by HFD with statistically significant (p < 0.01), 
and liver TC and TG remain unchanged. In 
hamster model, the TC, TG, LDL-C and HDL-C 
level in serum were markedly elevated. In 
addition, hepatic TC and TG level were 
significantly raised in hamster HLP models (p < 
0.01). 
 
Table 2: Growth parameters of all groups 
 
Parameter Mice Rats         Hamsters 
NC Model NC Model NC Model 
Initial body 
weight (g)* 
21.02 ± 0.98 20.88 ± 1.04 208.5 ± 11.72 207.96 ± 11.79 136.88 ± 7.64 134.97 ± 6.76 
Final body 
weight (g)# 
38.06 ± 2.08 37.23 ± 3.15 308.44 ± 25.63 304.12 ± 17.38 180.20 ± 10.50 176.77 ± 15.32 
Body weight 
gain (g) 




4.54 ± 0.29 4.71 ± 0.48 3.78 ± 0.48 3.51 ± 0.23 3.56 ± 0.23 3.45 ± 0.31 
The results are presented as the mean ± SD (n = 10). * Body weight at the beginning of the 4-week fed by high-fat-diet period. 
# Body weight at the end of the 4-week fed by high-fat-diet period 
 
Table 3: Lipids and lipoproteins levels in HFD-induced hyperlipidemia models 
 
Lipid Mice Rats Hamsters 
 NC Model NC Model NC Model 
Serum lipids     
TC (mmol/L) 2.87 ± 0.42 4.14 ± 0.94b 1.81 ± 0.33 4.17 ± 0.85b 5.11 ± 0.96 20.65 ± 10.49b 
TG (mmol/L) 0.46 ± 0.20 0.92 ± 0.22a 0.64 ± 0. 34 1.51 ± 0.35b 2.50 ± 0.19 6.42 ± 4.92b 
HDL-C (mmol/L) 2.11 ± 0.60 2.72 ± 0.95 0.81 ± 0.24 1.65 ± 0.81b 5.20 ± 1.41 9.56 ± 3.23b 
LDL-C (mmol/L) 1.14 ± 0.21 1.44 ± 0.55 1.63 ± 0.66 2.36 ± 0.90b 3.61 ± 1.34 8.21 ± 3.75b 
Liver lipids     
TC (mmol/L) 3.06 ± 0.84 3.59 ± 0.82 0.51 ± 0.12 0.76 ± 0.61 0.19 ± 0.04 1.02 ± 0.48b 
TG (mmol/L) 0.57 ± 0.36 1.08 ± 0.27b 2.26 ± 0.74 2.18 ± 0.95 0.08 ± 0.02 0.23 ± 0.11b 
The results are presented as the mean ± standard deviation obtained from ten mice in each group. All values are expressed as 
mean ± SEM ( n = 10 ); ap < 0.05, bp < 0.01 compared to the NC, normal control; Model, feed by high-fat diet; TC, total cholesterol; 
TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol 
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Expression on the hepatic mRNA levels of 3 
murine models fed with HFD 
 
The qPCR analysis was performed to measure 
the mRNA levels of hepatic genes of each model 
(Fig. 1). Compared with NC group, significant 
decrease were demonstrated in HMG-CR, 
CYP7A1, LCAT, and ApoAI mRNA levels in all 
model groups. In mice models, CYP7A1 mRNA 
levels were remarkably reduced in mice HLP 
model, whereas SR-BI, LDLR and ABCA1 were 
not affected by HFD. In the rat HLP model, 
expression of hepatic LDLR is suppressed by 
HFD, and mRNA level of LPL is slightly inhibited. 
In hamster model, it is noticeable that significant 
increase of LPL (12-fold p < 0.01) and decrease 
of HMG-CR, LCAT, ABCA1, LDLR (p < 0.05) and 
SR-BI (p < 0.05) mRNA levels were observed 
while compared with normal control. 
 
Histopathological changes in hyperlipidemic 
rats and hamsters  
 
A lot of lipid droplets were observed in the 
cytoplasm of centrilobular hepatocytes in livers 
from HFD-fed rats and hamsters, compared with 
those from animals fed a normal diet (Figure 2 b 
and d). The variation of size of hepatocyte 
significantly increased after long-term 
administration of HFD and the nucleus shrinkage 
presented. Liver cells show vacuolar 
degeneration and microvesicular fatty change in 
the HFD groups, which is more severe in the 
hamster liver (Figure 2d). 
 
 


















Figure 1: Analysis of hepatic mRNA levels using quantitative polymerase chain reaction in 3 HLP model groups. 
The 18S gene was used as an internal control. Relative mRNA levels are presented as the mean ± standard 
deviation obtained from eight animals in each group; ap < 0.05, bp < 0.01, vs. NC group. NC, normal control (See 






Figure 2: Pathological section ( HE staining ) from rats or hamsters liver of hyperlipidemia.( a ) NC, normal 
control of rats; ( b ) rats model fed by high-fat-diet; ( c ) NC, normal control of hamsters; ( d ) hamsters model fed 
by high-fat-diet. All images are shown at 200 × magnification 
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In the present study, we used modified HFD, 
which is based on routine formulation, to induce 
3 different murine hyperlipidemia (HLP) models. 
Compared with normal diet fed animals, a 
dramatic increase in serum TC, TG and LDL-C 
levels was observed (in Table 1) in 3 HLP 
models, and histopathological examination 
revealed evidently severe hepatic steatosis in the 
rat and hamster HFD-induced groups, indicating 
that HLP were successfully induced via 4-week 
administration of HFD in SD rats, NIH mice and 
hamster. Furthermore, hepatic steatosis, which is 
caused by long-term exposure to excessive fat in 
rat and hamster HLP models, represents the 
presence and the degree of metabolic 
dysfunction [20] in these models. Moreover, 
different expressive amount of RCT maker genes 
is responsible for the various HFD-induced 
phenotypic outcomes of 3 kinds of murine 
models.  
 
LDL and HDL are two kinds of lipoproteins in 
RCT, which are essential for whole-body 
cholesterol homeostasis maintenance. As the 
result presented, the alteration of mRNA level of 
RCT marker genes was highly associated with 
the changing value of serum LDL and HDL, 
which showed in all HFD models. Specifically, 
hepatic LDLR and SR-BI are two major 
membrane receptors responsible for uptake of 
serum LDL and HDL, which are a response to 
lipid metabolism and elimination. According to 
the result, neither LDLR nor SR-BI were affected 
by HFD in mice model, however, only LDLR was 
affected by HFD in rat model and both genes 
were dramatically inhibited by HFD in hamster 
HLP model. Given that serum LDL is the 
endogenous ligands of the LDLR and SR-BI, 
simultaneous decline of two transporters raises 
serum LDL content by blocking their 
transportation from blood to liver in the hamster 
model, which renders hamster more vulnerable 
in response to HFD. Moreover, HDL, whose 
formation is promoted by catalytic action of 
lecithin–cholesterol acyltransferase (LCAT) and 
is constructed with ApoA I, is protective factor for 
human HLP. Considering the decrease of LCAT 
and ApoA I but increase HDL concentration in 
hamster model, immature or dysfunctional HDL 
may be overly produced without eliminating 
cholesterol from blood.  In summary, the 
research finding strongly supported that 
hamsters are more vulnerable to HFD-induced 
hyperlipidemia and possesses priority in 
mimicking hyperlipidemia of human [21]. In other 
words, simultaneous decline of LDLR, SR-BI, 
ApoA I and LCAT and increase dysfunctional 
HDL sensitize hamsters to HFD-induced 
hyperlipidemia. Moreover, histopathological 
changes in HLP hamsters indicate that long-term 
exposure of HFD may cause severe hepatic 
steatosis. Given that hepatic steatosis can cause 
down-regulation of LDLR and SR-BI, and 
consequent HLP [22], the remedy for hepatic 
steatosis should be considered for preventing 
and curing HLP. Therefore, it is worthy to explore 
further mechanism of interaction between hepatic 
steatosis and LDLR, SRBI and LCAT, which is 
potential to find new therapeutic target for HLP. 
 
CYP7A1 is a liver specific enzyme that catalyzes 
the rate-limiting step in the biosynthesis of bile 
acid from cholesterol [23], and hepatic free 
cholesterol, which is released from HDL and LDL 
in RCT. Moreover, cholesterol necessarily 
undergoes this CYP7A1-induced conversion for 
further excretion. Thus, it is an important 
pathway for the elimination of cholesterol from 
the body. In our research, significant decline of 
CYP7A1 was observed in all the model groups, 
which indicates that hyperlipidemia is caused by 
hurdling elimination of hepatic HDL and LDL [24]. 
Noticeably, CYP7A1 of mice model shows more 
sensitive than two others in response to HFD. 
CYP7A1 is predominantly governed by nuclear 
receptor farnesoid X receptor (FXR) in mice, 
whereas it is dually mediated by FXR and LXR in 
rat and hamster which may guarantee stability of 
CYP7A1 in response to HFD. Therefore, 
CYP7A1 is more vulnerable to HFD in mice 
model. These results indicate mice HLP model is 
more valuable to evaluate the FXR agonist. 
 
HMG-CoA reductase (HMG-CR) is a rate-limiting 
enzyme in cholesterol synthesis which was 
confirmed through chemical and genetic methods 
to be a validated drug target for statins in S. 
mansoni [25]. The present study demonstrated 
that the mRNA expression of HMG-CR in all 
model groups were inhibited due to excessive 
absorption of exogenous cholesterol.   
Lipoprotein lipase (LPL), an enzyme bound to the 
capillary endothelium, hydrolyzes TGs in TG-rich 
plasma lipoproteins (TRLs). LPL also plays a role 
in HDL maturation by providing surface material 
from chylomicrons (CM) and VLDL during TG 
hydrolysis. In our investigation, there is no 
significant difference of LPL mRNA expression in 
mouse and rat groups, but the dramatic induced 
expression of LPL was observed in hamster, 
suggested that up-regulated of LPL may be 
mediated by increase of serum LDL. To confirm 
correlation between LPL or HMG-CR and HLP in 
hamster model, more study on their activity is 
needed. Unfortunately, the present study did not 
measure their activity, this correlation cannot be 
further explained. 
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The findings of this study evidently reveal that 
the pathogenesis of HFD-induced hyperlipidemia 
in murine models tightly correlate with 
impairment of RCT and hepatic steatosis, but it is 
unlikely that abnormal synthesis of endogenous 
cholesterol is engaged based on the decline of 
HMG-CR. In addition, HFD-induced HLP hamster 
model has priority in mimicking human HLP due 
to its similarity of phenotypic and genotypic 
alteration with human HLP. Based on the present 
findings, HFD-induced HLP hamster model is 
promising for exploration of a new therapeutic 
target for RCT disorder and development of 
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